Lawsuits Threaten ACS' Nonprofit Status, Financial Health

The American Chemical Society, whose members will gather in Washington, D.C., next week for the organization's 200th national meeting, is facing several legal attacks against its profitable Chemical Abstract Service. In June, Dialog Information Services, a California-based online information vendor, filed a $50 million suit against the society for "anticompetitive, illegal and predatory" management of CAS databases. The society is also fighting several law suits brought against it by the Columb

Written byJulia King
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The American Chemical Society, whose members will gather in Washington, D.C., next week for the organization's 200th national meeting, is facing several legal attacks against its profitable Chemical Abstract Service. In June, Dialog Information Services, a California-based online information vendor, filed a $50 million suit against the society for "anticompetitive, illegal and predatory" management of CAS databases. The society is also fighting several law suits brought against it by the Columbus (Ohio) Board of Education, which wants to overturn the service's real estate tax exemption.

The Columbus-based CAS, which is the society's largest division, publishes Chemical Abstracts, which since 1907 has printed more than 13 million abstracts and patent equivalents. Virtually all of the world's published chemical knowledge is contained within its pages and related registries, according to the society. Last year the service, with more than 25,000 research institutions as subscribers, generated a profit of more than $4 million ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies